



ASX Announcement and Media Release

Monday, 6 June, 2016

SciGen Ltd

CHANGE IN THE BOARD OF DIRECTORS

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce a change in the Board.

APPOINTMENT OF DIRECTOR

SciGen is pleased to announce the appointments of Dr. Marek Dziki as a Non-Executive Director of the Company.

Dr. Marek Dziki, is a medical doctor with a PhD from the University in Lublin, Poland. In 1998 he completed his MBA at the International Business School in Warsaw and in 2005 completed another MBA from Merck University (Kellog Business School, Chicago, Hong Kong University of Science and Technology and Business School in Fountainebleau).

Dr. Dziki has extensive experience in Pharmaceuticals, Chemicals, Life Science, Bioscience, Research & Development and Clinical Research Development. He started his career in with Merck in 1992. Between 1992 and 2000, he worked with Merck Poland, between 2001 and 2005 with Merck Austria, between 2005 and 2006 with Merck Darmstadt and from 2006 to 2012 was the Managing Director of Merck India. After leaving Merck, Dr Dziki was appointed as an executive director in Skolkovo Innovation Centre in Moscow working in close collaboration with the governmental institutions for the transfer of technology to Russia and for the development of strategy for the Russian biopharma development. Dr Dziki joined Lumedan (Zurich, Odessa and Moscow) as the CEO in 2013 and by 2015 became a consultant thereto. From March 2014, Dr. Dziki, is the President and Founder of M&M Pharma, Warsaw, a company dealing with disruptive innovation in new technology, emerging markets and financing. In February 2016, Dr Dziki was appointed as a Member of the Managing Board of Bioton S.A. overseeing all commercial operations.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen

focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638